Trial Profile
Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2019
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Skin ulcer
- Focus Registrational; Therapeutic Use
- Acronyms DUAL-2
- Sponsors Actelion Pharmaceuticals
- 10 May 2016 Primary endpoint of incidence rate of new digital ulcers (DUs) up to week 16 has not been met, according to results published in the JAMA: the Journal of the American Medical Association
- 10 May 2016 Results of DUAL-1 and DUAL-2 studies published in the JAMA: the Journal of the American Medical Association
- 14 Dec 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.